Core Viewpoint - The company is preparing to launch a first-class original new drug, Abanateptide, which has been featured in a promotional report by the "Changshan Metabolism" public account, along with interpretations from five top domestic diabetes experts [2]. Group 1 - The "Changshan Metabolism" WeChat public account is registered by the company's subsidiary, Changshan Kaijie Health Biotechnology (Beijing) Co., Ltd., focusing on the metabolism field and sharing academic information [2]. - The company encourages investors to follow the "Changshan Metabolism" public account for updates and information related to metabolic health [2].

证券日报网讯常山药业（300255）11月21日在互动平台回答投资者提问时表示，截至2025年11月20日， 公司的股东户数为47014户。 ...

证券之星消息，11月14日化学制药板块较上一交易日上涨0.32%，康芝药业领涨。当日上证指数报收于 3990.49，下跌0.97%。深证成指报收于13216.03，下跌1.93%。化学制药板块个股涨跌见下表： 从资金流向上来看，当日化学制药板块主力资金净流入6.8亿元，游资资金净流出4.13亿元，散户资金净 流出2.67亿元。化学制药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300584 海辰药业 | | 3.02亿 | 21.33% | -2.02 Z | -14.27% | -1.00 Z | -7.06% | | 300086 康芝药业 | | 2.55 Z | 20.57% | -1.52 Z | -12.26% | -1.03亿 | -8.31% | | 000566 海南海药 | | 2.43/Z | 37.31% | -1.15亿 | -17.60% | -1.28 乙 ...

2024年1至12月份，常山药业的营业收入构成为：生物医药占比86.96%，其他占比13.04%。 截至发稿，常山药业市值为541亿元。 每经头条（nbdtoutiao）——展望"十五五"|专访财科院院长杨志勇：遏制地方政府新增隐性债务，债务 信息要透明，尽可能降低利息成本 每经AI快讯，常山药业（SZ 300255，收盘价：58.9元）11月14日晚间发布公告称，公司第六届第五次 董事会会议于2025年11月14日在公司办公楼会议室现场结合通讯表决的方式召开。会议审议了《关于聘 任公司2025年度审计机构的议案》等文件。 （记者 曾健辉） ...

证券代码：300255 证券简称：常山药业 公告编号：2025-46 河北常山生化药业股份有限公司 拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 1．河北常山生化药业股份有限公司（以下简称公司）本次拟续聘会计师事务 所符合财政部、国务院国资委、证监会印发的《国有企业、上市公司选聘会计师 事务所管理办法》（财会〔2023〕4 号）的规定。 公司于 2025 年 11 月 14 日召开第六届董事会第五次会议，审议通过了《关于 聘任公司 2025 年度审计机构的议案》，同意续聘中喜会计师事务所（特殊普通合 伙）（以下简称中喜会计师事务所）为公司 2025 年度财务报告及内部控制审计机 构，并同意将该议案提交公司股东会审议，现将相关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构基本信息 事务所名称：中喜会计师事务所（特殊普通合伙） 成立日期：2013 年 11 月 28 日 组织形式：特殊普通合伙企业 注册地址：北京市东城区崇文门外大街 11 号 11 层 1101 室 首席合伙人：张增刚 截止 2024 年末，中喜会计师事务 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-47 河北常山生化药业股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、股东会的召集人：董事会 3、河北常山生化药业股份有限公司（以下简称公司）于 2025 年 11 月 14 日召开的第六届董事会第五次会议审议通过了《关于召开公司 2025 年第一次 临时股东会的议案》。本次股东会的召开符合有关法律法规、深圳证券交易所 业务规则和公司章程等规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 01 日 14:30:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2025 年 12 月 01 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2025 年 12 月 01 日 9:15 至 15:00 的任意 时间。 5、会议的召开方式：现场表决与网络投票相 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-45 河北常山生化药业股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 河北常山生化药业股份有限公司（以下简称公司）第六届董事会第五次会议 于 2025 年 11 月 14 日在公司办公楼会议室现场结合通讯表决的方式召开。本次 会议于 2025 年 11 月 11 日以邮件或直接送达的方式确保每一位董事收到本次会 议通知。与会的各位董事均已知悉与所议事项相关的必要信息。会议应参与表决 董事 6 名，实际参与表决董事 6 名。本次会议由公司董事长高晓东先生主持，符 合《公司法》及《公司章程》等规定。 会议以记名投票方式对各项议案进行表决，审议通过如下议案： 二、董事会会议审议情况 表决结果：6 票同意；0 票反对；0 票弃权。 2．审议通过《关于召开公司 2025 年第一次临时股东会的议案》 上述第 1 项议案及第六届董事会第四次会议审议通过的第 2 项、第 3 项、第 4 项、第 5 项、第 6 项、第 7 项议案需提交公司股东会 ...

Core Viewpoint - The pharmaceutical sector is experiencing active trading, with innovative drugs and biovaccines showing strong performance, indicating a positive outlook for the industry through 2026 [1] Industry Summary - The pharmaceutical sector has seen significant stock price increases, with companies like Chengda Pharmaceutical, Kangzhi Pharmaceutical, and Haichen Pharmaceutical reaching a 20% limit up, while others like Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also hit the limit up [1] - CITIC Securities forecasts that the investment trend in the pharmaceutical industry will continue to be driven by the concentration of innovation in Chinese pharmaceutical companies and supportive policies for innovative drugs and medical devices, leading to a stable domestic market environment [1] - The industry is expected to return to a market pricing system based on clinical value and demand, which will contribute to a stable and continuous growth trend in the performance of listed companies [1] Investment Strategy - The pharmaceutical industry is recommended for continued overweight positioning, with suggested investment themes for 2026 including: 1. Innovation-driven and internationalization, focusing on companies that are innovating and expanding internationally in a favorable domestic policy environment [1] 2. Self-sufficiency, with an emphasis on core components, reagents, and upstream research that can replace imports due to geopolitical risks [1] 3. New policies and new opportunities, targeting companies benefiting from optimized procurement, medical insurance payment reforms, consumption stimulus policies, and state-owned enterprise reforms [1]

Group 1 - The core point of the news is that Changshan Pharmaceutical experienced a stock price increase of 5.48%, reaching 56.56 CNY per share, with a trading volume of 1.093 billion CNY and a turnover rate of 2.18%, resulting in a total market capitalization of 51.982 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, specializes in the research, production, and sales of heparin series products, with its main business revenue composition being 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [1] Group 2 - From the perspective of major fund holdings, data shows that Guotai Fund has a significant position in Changshan Pharmaceutical, with the Guotai ChiNext Medical and Health ETF (159377) increasing its holdings by 19,500 shares in the third quarter, totaling 45,100 shares, which accounts for 4.75% of the fund's net value, ranking as the fifth-largest holding [2] - The Guotai ChiNext Medical and Health ETF (159377) was established on April 2, 2025, with a latest scale of 43.2788 million CNY and a cumulative return of 21.59% since inception [2]

Investment Rating - The report does not explicitly state an investment rating for the industry [1] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.4% from November 3 to November 7, 2025, underperforming compared to the Wind All A index (0.63%) and the CSI 300 index (0.82%) [2][7] - The rise in flu activity was noted, with the percentage of flu-like illness (ILI) cases reported at 4.7% in the week of October 27 to November 2, 2025, indicating an increase compared to previous weeks and years [2][10] - The final overall survival (OS) results from the HARMONi-A study of Ivosidenib combined with chemotherapy for EGFR-mutant non-small cell lung cancer showed a significant improvement in OS, with a median OS of 16.8 months versus 14.1 months for the control group [2][10] Weekly Market Review - The pharmaceutical and biotechnology sector's performance was down 2.4%, with notable declines in medical research outsourcing (-4.93%), chemical preparations (-4.42%), and other biological products (-4.33%) [7][8] - The leading gainers included Hezhi China (61.1%), Wanze Shares (30.3%), and Fuxiang Pharmaceutical (23.3%), while Changshan Pharmaceutical (-20%), Yifang Bio-U (-17.8%), and Guangshengtang (-15.3%) were the biggest losers [10] Industry News and Key Company Announcements - On November 7, 2025, the final OS analysis of the HARMONi-A study was presented, showing significant results for Ivosidenib in combination with chemotherapy [10][12] - According to data from the Chinese Center for Disease Control, flu-like illness percentages in southern provinces increased to 4.6%, while northern provinces reported 5.1%, both higher than the previous week [10][12] - BeiGene reported a total revenue of $1.412 billion for Q3 2025, a 41% year-on-year increase, driven by a 51% growth in global sales of its product [12][14] - Metsera announced a merger agreement with Pfizer, with an estimated total transaction value of approximately $9 billion [12][14]